Miyoshi Y, Nakao K
Department of Medicine and Clinical Science, Kyoto University School of Medicine, Japan.
Biochem Biophys Res Commun. 1997 Sep 8;238(1):39-43. doi: 10.1006/bbrc.1997.7184.
Although mutations of human thyroid hormone receptor beta (hTR beta) have been associated with resistance to thyroid hormone (RTH), the molecular basis by which the mutant TRs cause the various clinical symptoms is unknown. We show here that a mutant TR beta [corrected] identified in a patient with RTH inhibited the transcriptional activities of, not only the wild-type TR beta, but also other nuclear receptors including retinoid X receptor alpha (RXR alpha), vitamin D3 receptor (VDR) and retinoic acid receptor (RAR alpha). We provide evidence that these inhibitions by the mutant TR beta [corrected] occur by different mechanisms. Namely, the mutant TR beta interferes with VDR and RAR alpha by competition for binding to the corresponding response elements, but the pathway through RXR alpha is mainly inhibited by squelching of RXR alpha in solution. These findings suggest that in patients with RTH, not only the T3 responsive genes but also other responsive genes are inhibited by the mutant TRs, which might explain the variety of clinical symptoms in RTH.
虽然人类甲状腺激素受体β(hTRβ)突变与甲状腺激素抵抗(RTH)有关,但突变型TR导致各种临床症状的分子基础尚不清楚。我们在此表明,在一名RTH患者中鉴定出的突变型TRβ不仅抑制野生型TRβ的转录活性,还抑制包括视黄酸X受体α(RXRα)、维生素D3受体(VDR)和视黄酸受体(RARα)在内的其他核受体的转录活性。我们提供的证据表明,突变型TRβ的这些抑制作用通过不同机制发生。具体而言,突变型TRβ通过竞争结合相应反应元件来干扰VDR和RARα,但通过RXRα的途径主要通过溶液中RXRα的沉默来抑制。这些发现表明,在RTH患者中,不仅T3反应基因,其他反应基因也受到突变型TR的抑制,这可能解释了RTH中各种临床症状的原因。